MeDiCU Inc., which provides the world’s largest emergency and intensive care database “OneICU,” has entered into a business partnership with Chugai Pharmaceutical Co., Ltd. regarding data utilization.
It takes a huge amount of time and money to develop a new drug and put it into practical use, and streamlining clinical trials, which are the most time-consuming and cost-intensive part of the process, is a major challenge in drug discovery research. In particular, when developing drugs for emergency diseases where symptoms change rapidly, it tends to be difficult to find an appropriate patient group, and it is not uncommon for delays in the progress of clinical trials to delay the entire development process.
“OneICU,” which Chugai will now introduce, is the world’s largest medical big data collection, with biometric measurements from approximately 87,000 cases collected from patients in the ICUs (intensive care units) of eight university hospitals and core municipal hospitals across Japan. In addition to vital sign information measured once per minute, the database integrates and structures information from multiple facilities, which was previously thought to be nearly impossible to gather, including time-series data on therapeutic interventions in the ICU, severity scores, and outcomes at the time of discharge.
Also Read: KM Biologics Co., Ltd. introduces M2X
By utilizing “OneICU,” it will be possible to understand the characteristics of medical institutions to which many patients who are the subjects of clinical trials are transported and use this information for patient selection. It is also expected to contribute to the efficiency of clinical trials by making it possible to determine in advance the most effective timing for medication based on data organized chronologically on how a patient’s condition changes after admission to the ICU.
Through this partnership, we aim to realize higher quality medical care by streamlining the development of drugs to treat acute diseases, which will lead to the establishment of treatments for diseases that have been previously considered difficult to treat in the fields of emergency and intensive care.
SOURCE: PRTimes
